- $1.22bn
- $1.17bn
- $30.91m
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, CME
Verastem rises as combo therapy shows early benefit in pancreatic cancer
Brief: Verastem Oncology Doses First Patient In Target-D 201 Phase 2 Registration-Directed Trial Of Versus-7375 Oral Kras G12d (On/Off) Inhibitor
Verastem rises after FDA grants fast-track status for cancer drug
Brief: Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC
Verastem Q1 adjusted loss narrows smaller than expected on recording revenue
Brief: Verastem Oncology Announces Two-Year Median Follow-Up Data On Avmapki® Fakzynja® Combination Therapy
Brief: Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
U.S. RESEARCH ROUNDUP-Aerovironment, Bumble, Lumentum Holdings.
Verastem Q4 adjusted EPS beats analyst expectations
Brief: Verastem Oncology: Prelim Q4/2025 Rev And Business Updates; 2026 Priorities For Novel RAS/MAPK Pathway-Driven Cancer Portfolio
Brief: Verastem Oncology Provides Update On Ramp 203 Phase 1/2 Clinical Trial
Brief: Verastem Oncology Announces Transition Plan To Accelerate Next Phase Of Growth
U.S. STOCKS ON THE MOVE-Under Armour, GE Vernova, Walmart
U.S. STOCKS ON THE MOVE-Molina Healthcare, Memory chip makers, Binah Capital
U.S. STOCKS ON THE MOVE-Quantum, Septerna, Tripadvisor
Verastem Oncology drops after $90 mln stock sale
Brief: Verastem Oncology Prices Public Offering Of 8.5 Million Shares At $7.25 Each